Motivations, Expectations, and Decision-making of Sickle Cell Patients in Clinical Research
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03709303|
Recruitment Status : Recruiting
First Posted : October 17, 2018
Last Update Posted : September 19, 2019
Sickle cell disease is an inherited blood disorder. People with this disease have a problem with their hemoglobin. That is a protein in red blood cells that carries oxygen in the body. Some people with this disease are enrolled in research at NIH. Researchers want to learn more about the thoughts and opinions of those people. This may improve the way researchers explain clinical studies, risks, and benefits to people with the disease.
To learn about the motivations, decisions, and experiences in clinical research of people with sickle cell disease.
Adults ages 18 and older who have sickle cell disease. They must be in an NIH study on this condition. They must have been invited to join either a gene therapy or peripheral blood stem cell transplantation study.
Participants will have 1 interview. It will be done in a quiet room in the NIH Clinical Center or by video call. It will take about 60 minutes.
The interview will be audio-recorded if the participant agrees.
Participants will be asked about:
- Their experiences with and thoughts on sickle cell disease
- Their decision to participate in clinical research
- Factors that may have affected their decision to participate. These may include family, disease history, or faith.
Participants may complete a few brief questionnaires.
|Condition or disease|
|Sickle Cell Disease|
Clinical trials testing potentially curative interventions for sickle cell disease - such as gene therapy (GT) or peripheral blood stem cell transplantation (PBSCT) - have created a novel opportunity for patients with sickle cell disease, for whom standard therapies can only manage but not cure their conditions. But some of these experimental interventions may pose risk of significant adverse events. As the development of these interventions create a new decision-making situation for persons with longstanding diseases, these trials raise questions about the expectations and decision- making process of patients considering and/or participating in them. Given the longstanding debate in the bioethics literature about whether patients expressions of desire for benefit are (1) evidence of false hopes or poor understanding of risks and benefits, or, instead (2) expressions of natural optimism compatible with valid informed consent, these patients present an opportunity to learn about how they make their participation decisions which in turn could inform this longstanding debate.
This study aims to explore the expectations, understanding, motivations, and decision-making of patients with sickle cell disease who have either chosen or declined to enroll in research studies testing experimental interventions. The aim is to better understand how these patients understand the research study, assess risks and benefits at the time of enrollment, make decisions, and react to their health outcomes. As faith and religion are known to play an important part in the lives of persons with sickle cell disease, we will also explore the role of religion and faith in sickle cell patients decision-making and retrospective perspective on their decision.
This is a descriptive, explorative study. It may generate hypotheses for future studies.
Purpose of the Study Protocol:
To describe how patients with sickle cell disease understand and make decisions about participating in gene therapy (GT) or peripheral blood stem cell transplantation (PBSCT) clinical trials to shed light about the ethically salient issues regarding enrollment and participation in high- risk, high-reward clinical trials. This information may inform practices around the informed consent process and help researchers better understand the role of family and religion/faith in clinical research decision making.
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Official Title:||Motivations, Expectations, and Decision-making of Sickle Cell Patients in Clinical Research|
|Estimated Study Start Date :||September 24, 2019|
|Estimated Primary Completion Date :||August 31, 2020|
|Estimated Study Completion Date :||August 31, 2020|
Patients with sickle cell disease who have decided about enrollment in an NIH study of PBSCT or Gene therapy
- Expectations, understanding and motivations for enrollment [ Time Frame: Before or after enrollment in PBSCT or GT trial, but after decision made ]Understanding, expectations, motivations, and decision making process
- Explore the role of family and religion [ Time Frame: After decision made about enrollment ]Description of the role of family, culture, and religion in enrollment decision making
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03709303
|Contact: Hae L Cho||(301) email@example.com|
|United States, Maryland|
|National Institutes of Health Clinical Center||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR) 800-411-1222 ext TTY8664111010 firstname.lastname@example.org|
|Principal Investigator:||Christine Grady, Ph.D.||National Institutes of Health Clinical Center (CC)|